Opto-RTK-based treatment of Alzheimer's disease could involve delivery of opto-TrkA to the nucleus basalis of Meynert followed by activation with near-infrared light, so that only pro-survival signaling is activated6 (Fig. 4A). This evidence concerns the gene NTRK1 and early-onset autosomal dominant Alzheimer disease.